OrbusNeich Earns “Service and Innovative Product Awards 2025 – Medical Device Service Award” for Advancing Patient Care Through Innovation

(Hong Kong, July 11, 2025) – OrbusNeich Medical Group Holdings Limited (“OrbusNeich” or the “Group”; stock code: 6929.HK), a multinational medical device company specializing in interventional devices for percutaneous coronary intervention (“PCI”) and percutaneous transluminal angioplasty (“PTA”) procedures, is proud to announce recognition with the prestigious “Medical Device Service Award” at the Service and Innovative Product Awards 2025, hosted by Hong Kong’s leading business publication, Capital Magazine. This accolade celebrates OrbusNeich’s transformative contributions to healthcare through its patient-centric endovascular and structural heart solutions, which continue to redefine standards in global patient care.

With its relentless innovation, strong global presence and pioneering products portfolio, OrbusNeich stands as a trailblazer in endovascular innovation. Over the past year, the Group has introduced precision-driven technologies that enhance minimally invasive treatments. These advancements empower physicians worldwide to achieve superior clinical outcomes, improving lives across over 70 countries and regions.

Mr. David Chien, Chairman, Executive Director and Chief Executive Officer of OrbusNeich, remarked, “This award reflects our unwavering commitment to solving unmet clinical needs with innovation and compassion. Our recent strides, from pioneering technologies to expanding our global collaborative platform, underscore our mission to advance healthcare accessibility. At OrbusNeich, we develop solutions that prioritize long-term patient well-being while leveraging our worldwide network to introduce cutting-edge vascular interventions from both our portfolio and other manufacturers. This ensures patients and physicians everywhere benefit from transformative care and a broader range of treatment options, delivering greater benefits to the international healthcare ecosystem.” Organized by Capital Magazine, the Service and Innovative Product Awards honor excellence in innovation, service, and industry leadership. OrbusNeich’s recognition underscores its dual commitment to pioneering in life-changing technologies and delivering exceptional customer service, driving advancements in global healthcare standards and improving patient outcomes worldwide.

Mr. Jason Chen, Executive Director and Chief Financial Officer of OrbusNeich (left), receives the “Service and Innovative Product Award 2025” on behalf of the Group.

－ End －

About OrbusNeich Medical Group Holdings Limited
OrbusNeich is a multinational medical device company specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. Headquartered in Hong Kong, China, our Group sells its products in more than 70 countries and regions worldwide. It is also actively expanding into structural heart disease. With an in-house R&D team boasting over 20 years of product development expertise, our Group has developed world-leading proprietary technologies.